4-Star Stocks Poised to Pop: Vertex Pharmaceuticals

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer Vertex Pharmaceuticals (Nasdaq: VRTX  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Vertex and see what CAPS investors are saying about the stock right now.

Vertex facts

Headquarters (founded)

Cambridge, Mass. (1989)

Market Cap

$9.7 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$1.8 billion

Management

Chairman/CEO Jeffrey Leiden
CFO Ian Smith

Return on Equity (average, past 3 years)

(12%)

Cash / Debt

$1.3 billion / $400 million

Competitors

Bristol-Myers Squibb (NYSE: BMY  )
Merck
(NYSE: MRK  )
PTC Therapeutics

Sources: S&P Capital IQ; Motley Fool CAPS.

On CAPS, 92% of the 741 members who have rated Vertex believe the stock will outperform the S&P 500 going forward.

Just last week, one of those bulls, All-Star zzlangerhans, highlighted the stock as an intriguing pick for Fools with a stomach for risk:

Trading Vertex now is like the old days, when the valuation rose and fell based on prospects rather than sales. It's pretty clear that Incivek isn't the yellow brick road to sustained profitability that it appeared to be a couple of years ago. ... I still like the potential of interferon-free Incivek regimens, the cystic fibrosis franchise, and late stage trials of JAK inhibitor VX-509 in [rheumatoid arthritis] and influenza.

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Vertex may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2095351, ~/Articles/ArticleHandler.aspx, 9/23/2014 12:31:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement